citalopram has been researched along with escitalopram in 53 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (11.32) | 24.3611 |
| 2020's | 47 (88.68) | 2.80 |
| Authors | Studies |
|---|---|
| Cyriac, G; Javitch, JA; Katz, JL; Kopajtic, T; Newman, AH; Zhang, P; Zhao, Y | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Bang-Andersen, B; Frederiksen, K; Hogg, S; Jensen, KG; Jørgensen, M; Mørk, A; Nielsen, SM; Ruhland, T; Smith, G; Stensbøl, TB; Zhong, H | 1 |
| Banala, AK; Cyriac, G; Katz, JL; Kopajtic, T; Loland, CJ; Newman, AH; Plenge, P; Zhang, P | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bang-Andersen, B; Bregnedal, P; Bøgesø, KP; Juhl, K; Larsen, K; Loland, CJ; Plenge, P; Sanchez, C; Topiol, S | 1 |
| Grzenda, A; Laird, KT; Lavretsky, H; Siddarth, P; Yeargin, J | 1 |
| Anderson, HD; Campbell, JD; Czaja, AS; Davidson, J; Ghosh, D; Valuck, RJ | 1 |
| Ahn, SH; Cha, JK; Chang, DI; Choi-Kwon, S; Heo, JH; Kim, DE; Kim, HY; Kim, J; Kim, JS; Kim, JY; Kim, MS; Kim, S; Koh, SH; Kwon, DY; Lee, BC; Lee, EJ; Lee, J; Lee, JS; Park, JH; Park, SW; Seo, WK; Sohn, SI | 1 |
| Kennedy, SH; Larsen, KG; Reines, EH; Thase, ME | 1 |
| Bosi, MF; Cafaro, R; Cetin, I; Clementi, E; Colombo, A; Dell'Osso, B; Di Bernardo, I; Giordano, F; Giorgetti, F; Pileri, P; Varinelli, A; Viganò, CA | 1 |
| Berrocoso, E; Desco, M; Mico, JA; Perez-Caballero, L; Soto-Montenegro, ML | 1 |
| Bousman, CA; Li, JT; Lin, JY; Liu, Q; Lv, XZ; Si, TM; Su, YA; Tian, L; Yu, X | 1 |
| Amano, T; Nakatani, Y | 1 |
| Haas, DM; Marks, C; Quinney, SK; Silvola, R; Teal, E | 1 |
| Cao, L; Chen, Y; Fang, Y; Hong, W; Huang, H; Huang, Q; Kong, S; Lyu, D; Peng, D; Qian, N; Wang, F; Wei, Z; Wu, C; Wu, Z; Yang, W; Zhang, M; Zhao, J | 1 |
| Hsu, CW; Kao, HY; Lin, PY; Tseng, WT; Wang, LJ; Yang, YH | 1 |
| Alaie, I; Antoni, G; Faria, V; Fredrikson, M; Frick, A; Furmark, T; Gingnell, M; Hjorth, OR; Hoppe, JM; Hultberg, S; Jonasson, M; Lubberink, M; Månsson, KNT; Reis, M; Rosén, J; Wahlstedt, K | 1 |
| Becker, AM; Duthaler, U; Eckert, A; Grandinetti, T; Grünblatt, E; Holze, F; Klaiber, A; Kolaczynska, KE; Liechti, ME; Toedtli, VE; Varghese, N | 1 |
| Mori, Y; Ochiai, S | 1 |
| Deng, S; Fu, T; Xue, W; Yang, F; Yang, J; Zhu, F | 1 |
| Beinhölzl, N; Cesnaite, E; Molloy, EN; Nikulin, VV; Piecha, FA; Regenthal, R; Sacher, J; Scharrer, U; Villringer, A; Zheleva, G; Zsido, RG | 1 |
| Asada, R; Hori, H; Kawasaki, H; Ogushi, Y | 1 |
| Bleich, S; Bridler, R; de Bardeci, M; Greil, W; Grohmann, R; Hasler, G; Kasper, S; Köberle, U; Rüther, E; Seifert, J; Stassen, H; Toto, S; Willms, J | 1 |
| Chen, X; Feng, L; Feng, Y; Sun, Z; Xiao, L; Yang, J; Zhou, J | 1 |
| Al-Khatib, SM; Assimon, MM; Brookhart, MA; Flythe, JE; Gaynes, BN; Pun, PH; Winkelmayer, WC | 1 |
| Cipelli, R; Dell'Osso, B; Di Nicola, M; Martinotti, G; Peduto, I; Pugliese, AC; Signorelli, MS; Ventriglio, A | 1 |
| Bhat, V; Diep, C; Frey, BN; Gandhi, W; Kennedy, SH; Khoo, Y; Ladha, KS; Lam, RW; Lou, W; Milev, RV; Ravindran, AV; Rosenek, N; Rotzinger, S; Salomons, T; van Reekum, CM | 1 |
| Cho, RY; Fang, F; Godlewska, B; Savitz, SI; Selvaraj, S; Zhang, Y | 1 |
| Bhat, V; Demchenko, I; Espinola, CW; Frey, BN; Ho, K; Kennedy, SH; Khoo, Y; Lam, RW; Lou, W; Milev, RV; Parikh, SV; Parmar, R; Ravindran, AV; Rotzinger, S | 1 |
| Blumenthal, JA; Davidson, J; Hinderliter, A; Hoffman, BM; Jiang, W; Kraus, WE; Liao, L; Mabe, S; Sherwood, A; Smith, PJ; Watkins, LL | 1 |
| Banner, J; Johansen, SS; Linnet, K; Nielsen, MKK; Rygaard, K | 1 |
| Aakjaer, M; Andersen, M; De Bruin, ML; Werther, SK | 1 |
| Bryun, EA; Horyaev, DS; Ivanchenko, VA; Noskov, VV; Pankratenko, EP; Petukhov, AE; Pozdniakov, SA; Rwere, F; Skryabin, V; Sychev, DA; Vinokurova, NV; Vlasovskih, RV; Zastrozhin, MS; Zaytsev, IA | 1 |
| Courtet, P; Guillaume, S; Lengvenyte, A; Olie, E; Strumila, R | 1 |
| Belz, M; Degner, D; Greil, W; Grohmann, R; Köberle, U | 1 |
| Dörfler, S; Gründer, G; Hart, XM; Havemann-Reinecke, U; Heesen, S; Hiemke, C; Schmitz, CN; Wedekind, D | 1 |
| Faraj, P; Hermansen, A; Hole, K; Molden, E | 1 |
| Cai, JF; Chen, GB; He, JK; Hou, XB; Jiao, Y; Jin, GX; Liu, Y; Qin, ZS; Rong, PJ; Shi, L; Wang, Y; Wong, YK; Xiao, HB; Xiao, X; Xu, FQ; Yang, XJ; Zhang, JN; Zhang, LL; Zhang, SY; Zhang, ZJ; Zhao, YY; Zheng, Y | 1 |
| Armand, S; Borgsted, C; Cardinal, RN; Johansen, A; Knudsen, GM; Langley, C; Luo, Q; Overgaard-Hansen, O; Pedersen, EB; Robbins, TW; Sahakian, BJ; Savulich, G; Segerberg, T; Stenbæk, DS; Svart, N; Søndergaard, A | 1 |
| Armand, S; Frokjaer, VG; Giraldi, A; Joergensen, MB; Knudsen, GM; Nielsen, JH; Stenbaek, DS; Weber, S | 1 |
| Artursson, P; Blumenfeld, Z; Cohen, BN; Dougherty, DA; Grant, SN; Hammar, R; Kim, CH; Knox, HJ; Lester, HA; Looger, L; Luebbert, L; Marvin, JS; Muthusamy, AK; Nichols, AL; Walton, DP | 1 |
| Amann, F; Brand, J; Eichentopf, L; Gründer, G; Hart, XM | 1 |
| Ayaz, F; Önal, HT; Yetkin, D | 1 |
| Bertzos, K; Eisenberg, B; Gopalkrishnan, M; Greenberg, E; Hahn, RD; Knutson, JA; Liu, C; McVoy, M; Moldauer, L; Strawn, JR; Wise, A | 1 |
| Christensen, KS; Gasse, C; Ishtiak-Ahmed, K | 1 |
| Choi, JY; Han, SJ; Kang, KJ; Lee, N; Nam, KR; Oh, SJ | 1 |
| Aljabali, AAA; Alqudah, A; Altaber, S; Gammoh, O; Ibrahim, A; Qnais, E; Tambuwala, MM | 1 |
| Conway, C; Elson, D; Kang, H; Sudol, K; Szymkowicz, SM; Taylor, WD | 1 |
| Boyce, P; Galbally, M; Nguyen, T; Watson, SJ | 1 |
| Dietrichs, ES; Faraj, P; Hole, K; Molden, E; Smith, G; Størset, E | 1 |
| Lu, Z; Wang, Y; Xun, G | 1 |
| Lin, X; Miao, M; Song, X; Wang, C; Yin, J | 1 |
2 review(s) available for citalopram and escitalopram
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis.
Topics: Antidepressive Agents; Citalopram; Depressive Disorder, Major; Escitalopram; Humans; Selective Serotonin Reuptake Inhibitors | 2023 |
17 trial(s) available for citalopram and escitalopram
| Article | Year |
|---|---|
Transcriptomic signatures of treatment response to the combination of escitalopram and memantine or placebo in late-life depression.
Topics: Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Memantine; Transcriptome; Treatment Outcome | 2021 |
Post-Stroke Depressive Symptoms: Varying Responses to Escitalopram by Individual Symptoms and Lesion Location.
Topics: Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Selective Serotonin Reuptake Inhibitors; Stroke; Treatment Outcome | 2021 |
Patient Response Trajectories in Major Depressive Disorder.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Treatment Outcome | 2020 |
Difference in the regulation of biological rhythm symptoms of Major depressive disorder between escitalopram and mirtazapine.
Topics: Circadian Rhythm; Citalopram; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Mirtazapine; Treatment Outcome | 2022 |
Comparative effectiveness of antidepressants on geriatric depression: Real-world evidence from a population-based study.
Topics: Aged; Antidepressive Agents; Citalopram; Depression; Escitalopram; Humans; Sertraline; Treatment Outcome | 2022 |
Expectancy effects on serotonin and dopamine transporters during SSRI treatment of social anxiety disorder: a randomized clinical trial.
Topics: Citalopram; Dopamine; Escitalopram; Female; Humans; Male; Phobia, Social; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins | 2021 |
Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects.
Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Citalopram; Cross-Over Studies; Double-Blind Method; Escitalopram; Healthy Volunteers; Humans; Psilocybin | 2022 |
One-week escitalopram intake alters the excitation-inhibition balance in the healthy female brain.
Topics: Brain; Citalopram; Double-Blind Method; Escitalopram; Female; Humans; Selective Serotonin Reuptake Inhibitors | 2022 |
Pain severity and pain interference during major depressive episodes treated with escitalopram and aripiprazole adjunctive therapy: a CAN-BIND-1 report.
Topics: Antidepressive Agents; Aripiprazole; Citalopram; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Escitalopram; Humans; Pain; Pain Measurement; Treatment Outcome | 2022 |
Males and females differ in reported sexual functioning with escitalopram treatment for major depressive disorder: A CAN-BIND-1 study report.
Topics: Antidepressive Agents; Citalopram; Cross-Sectional Studies; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Female; Humans; Male; Treatment Outcome | 2022 |
Longer term benefits of exercise and escitalopram in the treatment of anxiety in patients with coronary heart disease: Six month follow-up of the UNWIND randomized clinical trial.
Topics: Anxiety; Citalopram; Coronary Disease; Escitalopram; Exercise; Follow-Up Studies; Humans; Selective Serotonin Reuptake Inhibitors | 2022 |
Escitalopram should be investigated in anorexia nervosa: Rationale and review of mechanisms.
Topics: Anorexia Nervosa; Citalopram; Double-Blind Method; Escitalopram; Humans; Selective Serotonin Reuptake Inhibitors; Serotonin | 2022 |
Transcutaneous electrical cranial-auricular acupoint stimulation versus escitalopram for mild-to-moderate depression: An assessor-blinded, randomized, non-inferiority trial.
Topics: Acupuncture Points; Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Treatment Outcome | 2023 |
Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study.
Topics: Bayes Theorem; Citalopram; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Healthy Volunteers; Humans; Infant, Newborn; Selective Serotonin Reuptake Inhibitors | 2023 |
Sexual function improves as depressive symptoms decrease during treatment with escitalopram: results of a naturalistic study of patients with major depressive disorder.
Topics: Antidepressive Agents; Citalopram; Depression; Depressive Disorder, Major; Escitalopram; Humans; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunction, Physiological | 2023 |
A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder.
Topics: Adolescent; Anxiety Disorders; Child; Citalopram; Double-Blind Method; Escitalopram; Humans; Nucleotidyltransferases; Treatment Outcome | 2023 |
Effect of aripiprazole on promoting cognitive function and enhancing clinical efficacy in patients with first-episode depression on escitalopram: A randomized controlled trial.
Topics: Antidepressive Agents; Aripiprazole; Citalopram; Cognition; Depression; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Treatment Outcome | 2024 |
34 other study(ies) available for citalopram and escitalopram
| Article | Year |
|---|---|
Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile) analogues at monoamine transporters.
Topics: Amino Acid Transport Systems; Animals; Bacterial Proteins; Binding, Competitive; Brain; Citalopram; Dopamine Plasma Membrane Transport Proteins; In Vitro Techniques; Leucine; Ligands; Models, Molecular; Norepinephrine Plasma Membrane Transport Proteins; Protein Binding; Radioligand Assay; Rats; Serotonin Plasma Membrane Transport Proteins; Stereoisomerism; Structure-Activity Relationship | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
Topics: Animals; Antidepressive Agents; Cell Line; Depressive Disorder, Major; Drug Partial Agonism; Drug Stability; Hippocampus; Humans; In Vitro Techniques; Microsomes, Liver; Oocytes; Piperazines; Radioligand Assay; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Receptors, Serotonin, 5-HT3; Recombinant Proteins; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT3 Receptor Antagonists; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship; Sulfides; Vortioxetine; Xenopus | 2011 |
Design and synthesis of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile (citalopram) analogues as novel probes for the serotonin transporter S1 and S2 binding sites.
Topics: Allosteric Site; Animals; Binding Sites; Brain; Chlorocebus aethiops; Citalopram; COS Cells; Humans; Serotonin Plasma Membrane Transport Proteins | 2013 |
X-ray structure based evaluation of analogs of citalopram: Compounds with increased affinity and selectivity compared with R-citalopram for the allosteric site (S2) on hSERT.
Topics: Allosteric Site; Binding Sites; Citalopram; Crystallography, X-Ray; Drug Design; Humans; Inhibitory Concentration 50; Molecular Dynamics Simulation; Protein Structure, Tertiary; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Stereoisomerism; Structure-Activity Relationship | 2017 |
Increased Odds of Ventricular Arrhythmias Associated with Selective Serotonin Reuptake Inhibitor Use among the Pediatric and Young Adult Population: A Case-Control Study.
Topics: Adolescent; Age Factors; Arrhythmias, Cardiac; Case-Control Studies; Child; Child, Preschool; Citalopram; Escitalopram; Female; Hospitalization; Humans; Logistic Models; Male; Odds Ratio; Risk Factors; Selective Serotonin Reuptake Inhibitors; Young Adult | 2020 |
Correlation between pharmacokinetics and pharmacogenetics of Selective Serotonin Reuptake Inhibitors and Selective Serotonin and Noradrenaline Reuptake Inhibitors and maternal and neonatal outcomes: Results from a naturalistic study in patients with affec
Topics: Citalopram; Escitalopram; Female; Humans; Mood Disorders; Pharmacogenetics; Pregnancy; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin and Noradrenaline Reuptake Inhibitors | 2021 |
Sustained escitalopram administration affects glucose metabolism in the rat brain.
Topics: Animals; Antidepressive Agents; Brain; Citalopram; Escitalopram; Glucose; Humans; Male; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors | 2021 |
Anxiety symptom remission is associated with genetic variation of PTPRZ1 among patients with major depressive disorder treated with escitalopram.
Topics: Anxiety; Citalopram; Depressive Disorder, Major; Escitalopram; Genetic Variation; Genome-Wide Association Study; Humans; Receptor-Like Protein Tyrosine Phosphatases, Class 5; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2021 |
Contributions of S- and R-citalopram to the citalopram-induced modulation of the function of Nav1.5 voltage-gated sodium channels.
Topics: Citalopram; Escitalopram; HEK293 Cells; Humans; NAV1.5 Voltage-Gated Sodium Channel; Selective Serotonin Reuptake Inhibitors | 2021 |
Comparing newborn outcomes after prenatal exposure to individual antidepressants: A retrospective cohort study.
Topics: Antidepressive Agents; Bupropion; Citalopram; Duloxetine Hydrochloride; Escitalopram; Female; Fluoxetine; Humans; Infant, Newborn; Pregnancy; Prenatal Exposure Delayed Effects; Retrospective Studies; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2021 |
Escitalopram for repeated stealing in an elderly man with an existing cerebral contusion.
Topics: Aged; Brain Contusion; Citalopram; Escitalopram; Humans; Male; Theft | 2022 |
Molecular Mechanism for the Allosteric Inhibition of the Human Serotonin Transporter by Antidepressant Escitalopram.
Topics: Allosteric Regulation; Allosteric Site; Antidepressive Agents; Citalopram; Escitalopram; Humans; Molecular Dynamics Simulation; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins | 2022 |
Successful treatment for major depressive disorder with psychotic features with addition of asenapine on escitalopram.
Topics: Antipsychotic Agents; Citalopram; Depressive Disorder, Major; Dibenzocycloheptenes; Double-Blind Method; Escitalopram; Humans; Treatment Outcome | 2022 |
Dear Doctor Letters regarding citalopram and escitalopram: guidelines vs real-world data.
Topics: Aged; Citalopram; Depressive Disorder, Major; Escitalopram; Humans; Long QT Syndrome; Psychotropic Drugs; Quetiapine Fumarate | 2023 |
The association of C-reactive protein with responses to escitalopram antidepressant treatment in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; C-Reactive Protein; Citalopram; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Follow-Up Studies; Humans; Prospective Studies; Treatment Outcome | 2022 |
Proton pump inhibitors may enhance the risk of citalopram- and escitalopram-associated sudden cardiac death among patients receiving hemodialysis.
Topics: Adult; Antidepressive Agents; Citalopram; Death, Sudden, Cardiac; Escitalopram; Humans; Proton Pump Inhibitors; Renal Dialysis; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline | 2022 |
Adherence to, and Persistence of, Antidepressant Therapy in Patients with Major Depressive Disorder: Results from a Population-based Study in Italy.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Escitalopram; Humans; Italy; Paroxetine; Retrospective Studies; Sertraline; Venlafaxine Hydrochloride; Vortioxetine | 2023 |
Effects of escitalopram therapy on functional brain controllability in major depressive disorder.
Topics: Antidepressive Agents; Brain; Citalopram; Depressive Disorder, Major; Escitalopram; Humans; Magnetic Resonance Imaging | 2022 |
Concentrations of citalopram and escitalopram in postmortem hair segments.
Topics: Chromatography, High Pressure Liquid; Citalopram; Escitalopram; Hair; Humans; Selective Serotonin Reuptake Inhibitors; Tandem Mass Spectrometry | 2022 |
Serious arrhythmia in initiators of citalopram, escitalopram, and other selective serotonin reuptake inhibitors: A population-based cohort study in older adults.
Topics: Aged; Arrhythmias, Cardiac; Citalopram; Cohort Studies; Escitalopram; Humans; Selective Serotonin Reuptake Inhibitors | 2022 |
Influence of
Topics: Citalopram; Cytochrome P-450 CYP2C19; Depressive Disorder; Escitalopram; Humans; Polymorphism, Genetic; Tandem Mass Spectrometry | 2022 |
[Effect of the direct healthcare professional communication on citalopram and escitalopram drug utilization for inpatient treatment of anxiety disorders].
Topics: Anxiety Disorders; Citalopram; Communication; Delivery of Health Care; Drug Utilization; Escitalopram; Germany; Humans; Inpatients | 2022 |
Concentrations of escitalopram in blood of patients treated in a naturalistic setting: focus on patients with alcohol and benzodiazepine use disorder.
Topics: Benzodiazepines; Citalopram; Depressive Disorder, Major; Escitalopram; Ethanol; Humans; Retrospective Studies | 2023 |
Identification of Escitalopram Metabolic Ratios as Potential Biomarkers for Predicting CYP2C19 Poor Metabolizers.
Topics: Biomarkers; Citalopram; Cytochrome P-450 CYP2C19; Escitalopram; Genotype; Humans | 2022 |
Selective Serotonin Reuptake Inhibitors within Cells: Temporal Resolution in Cytoplasm, Endoplasmic Reticulum, and Membrane.
Topics: Animals; Citalopram; Depressive Disorder, Major; Endoplasmic Reticulum; Escitalopram; Fluoxetine; Humans; Mammals; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins | 2023 |
Low Escitalopram Concentrations in Patients with Depression predict Treatment Failure: A Naturalistic Retrospective Study.
Topics: Citalopram; Cross-Sectional Studies; Depression; Escitalopram; Humans; Retrospective Studies; Treatment Failure | 2023 |
Escitalopram's inflammatory effect on the mammalian macrophages and its intracellular mechanism of action.
Topics: Animals; Antidepressive Agents; Citalopram; Cytokines; Escitalopram; Humans; Macrophages; Mammals; Phosphatidylinositol 3-Kinases; Selective Serotonin Reuptake Inhibitors | 2023 |
Do sociodemographic and clinical factors affect the selection of initial antidepressant treatment for depression in older adults? Results from a nationwide descriptive study in Denmark.
Topics: Aged; Antidepressive Agents; Citalopram; Cross-Sectional Studies; Denmark; Depression; Escitalopram; Humans; Mirtazapine; Sertraline | 2023 |
Effects of Escitalopram on the Functional Neural Circuits in an Animal Model of Adolescent Depression.
Topics: Animals; Citalopram; Depression; Disease Models, Animal; Escitalopram; gamma-Aminobutyric Acid; Glutamates | 2023 |
Vitamins C and D Exhibit Similar Antidepressant Effects to Escitalopram Mediated by NOx and FKBPL in a Stress-Induced Mice Model.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Ascorbic Acid; Cell Cycle Proteins; Citalopram; Depression; Escitalopram; Mice; Vitamin D; Vitamins | 2023 |
Cognitive, Disability, and Treatment Outcome Implications of Symptom-Based Phenotyping in Late-Life Depression.
Topics: Aged; Anhedonia; Citalopram; Cognition; Depression; Escitalopram; Fatigue; Humans; Sleep Initiation and Maintenance Disorders; Treatment Outcome | 2023 |
Fetal SSRI antidepressant exposure and infant sleep: Findings from the MPEWS pregnancy cohort study.
Topics: Antidepressive Agents; Citalopram; Cohort Studies; Escitalopram; Female; Humans; Infant; Longitudinal Studies; Pregnancy; Selective Serotonin Reuptake Inhibitors; Sertraline; Sleep | 2023 |
Pro-arrhythmic effect of escitalopram and citalopram at serum concentrations commonly observed in older patients - a study based on a cohort of 19,742 patients.
Topics: Action Potentials; Adolescent; Adult; Aged; Aged, 80 and over; Cardiotoxicity; Child; Citalopram; Escitalopram; Heart Arrest; Humans; Middle Aged; Myocytes, Cardiac; Prodrugs; Young Adult | 2023 |